Tazemetostat Hydrobromide
FDA-approved product (tablet, oral), marketed as Tazverik.
- Registered studies
- 3
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Follicular lymphoma
- Neoplasm
- Sarcoma
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other antineoplastic agents
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA64.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli50.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae36.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis49.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
3registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Tazemetostat Hydrobromide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- UrsodiolExisting use: Biliary liver cirrhosis, Primary biliary cirrhosis69.2% AI-predicted activityagainst MRSA50+ registered studies
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more69.2% AI-predicted activityagainst MRSA50+ registered studies
- Ganirelix AcetateExisting use: Female infertility, Positive regulation of ovulation, Reproductive Techniques, Assisted69.1% AI-predicted activityagainst MRSA50+ registered studies
- DanicopanExisting use: Acquired paroxysmal nocturnal hemoglobinuria, Hemoglobinuria, Paroxysmal, Hemolysis68.7% AI-predicted activityagainst MRSA30 registered studies
- Simeprevir SodiumExisting use: Chronic hepatitis C virus infection68.6% AI-predicted activityagainst MRSANo documented evidence found
- Lanreotide AcetateExisting use: Acromegaly, Carcinoid syndrome68.3% AI-predicted activityagainst MRSA50+ registered studies
- Cholic AcidExisting use: Abnormality of the gastrointestinal tract, Inborn errors of metabolism, Liver disease and 1 more68.0% AI-predicted activityagainst MRSA50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more67.8% AI-predicted activityagainst MRSA35 registered studies
- AbarelixExisting use: Neoplasm67.7% AI-predicted activityagainst MRSA5 registered studies
- EverolimusExisting use: Adenoma sebaceum, Anaplastic astrocytoma, Angiomyolipoma and 18 more67.5% AI-predicted activityagainst MRSA50+ registered studies
- Paliperidone PalmitateExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.3% AI-predicted activityagainst MRSA50+ registered studies
- PaliperidoneExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Tazemetostat Plus CHOP in 1L T-cell Lymphoma
NCT06692452 · start 2024-12-24
Registered record
- Registry ID
- NCT06692452
- Conditions
- Lymphoma; Peripheral T Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Enteropathy-Associated T-Cell Lymphoma; Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma
- Interventions
- Tazemetostat; Doxorubicin; Vincristine; Prednisone; Cytoxan; Carmustine; Etoposide; Cytarabine; Melphalan
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Withdrawn
- Start
- 2024-12-24
- Completion
- 2032-10-01
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLymphoma; Peripheral T Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Enteropathy-Associated T-Cell Lymphoma +1 moreInterventionTazemetostat; Doxorubicin; Vincristine; Prednisone +5 morePhasePhase 2Registry statusWithdrawnTesting of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer
NCT05353439 · start 2022-07-27
Registered record
- Registry ID
- NCT05353439
- Conditions
- Extensive Stage Lung Small Cell Carcinoma; Limited Stage Lung Small Cell Carcinoma; Platinum-Resistant Lung Small Cell Carcinoma; Platinum-Sensitive Lung Small Cell Carcinoma; Recurrent Extensive Stage Lung Small Cell Carcinoma; Recurrent Lung Small Cell Carcinoma
- Interventions
- Biopsy Procedure; Biospecimen Collection; Computed Tomography; Pembrolizumab; Tazemetostat Hydrobromide; Topotecan Hydrochloride
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Active not recruiting
- Start
- 2022-07-27
- Completion
- 2027-03-13
- Enrolment
- 18
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionExtensive Stage Lung Small Cell Carcinoma; Limited Stage Lung Small Cell Carcinoma; Platinum-Resistant Lung Small Cell Carcinoma; Platinum-Sensitive Lung Small Cell Carcinoma +2 moreInterventionBiopsy Procedure; Biospecimen Collection; Computed Tomography; Pembrolizumab +2 morePhasePhase 1Registry statusActive not recruitingTesting the Addition of the Anti-cancer Drug, Tazemetostat, to (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment
NCT04557956 · start 2021-08-19
Registered record
- Registry ID
- NCT04557956
- Conditions
- Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Melanoma
- Interventions
- Biopsy Procedure; Computed Tomography; Dabrafenib Mesylate; Echocardiography Test; Magnetic Resonance Imaging; Multigated Acquisition Scan; Tazemetostat Hydrobromide; Trametinib Dimethyl Sulfoxide
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Active not recruiting
- Start
- 2021-08-19
- Completion
- 2027-03-11
- Enrolment
- 16
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionClinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic MelanomaInterventionBiopsy Procedure; Computed Tomography; Dabrafenib Mesylate; Echocardiography Test +4 morePhasePhase 1 / Phase 2Registry statusActive not recruiting